Results 231 to 240 of about 52,475 (270)

Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin‐K antagonists: A retrospective German claims data analysis

Christiane Engelbertz, Ursula Marschall, Jannik Feld, Lena Makowski, Stefan A. Lange, Eva Freisinger, Joachim Gerß, Günter Breithardt, Andreas Faldum, Holger Reinecke, Jeanette Köppe   +10 more
openalex   +1 more source

Cu-diamine ligand-controlled asymmetric Henry reactions and their application in concise total syntheses of linezolid and rivaroxaban. [PDF]

RSC Adv
Zhang Y, Xiao W.
europepmc   +1 more source

Plain language summary of the direct oral anticoagulant switch study: effect of switching or continuing apixaban or rivaroxaban among people with non-valvular atrial fibrillation. [PDF]

Future Cardiol
Deitelzweig S, Jiang J, Subash R, Cheng D, Lip GYH.   +4 more
europepmc   +1 more source

Anticoagulantia, een veld in beweging [PDF]

, 2010
Christiaens, Thierry, De Backer, Tine
core  

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database. [PDF]

Hematol Rep
Olimpieri PP, Palumbo FE, Giuffrida G, Milanetti E, Gozzo C, Scebba EL, Romano GL, Lombardo GE, Duminuco A, Vetro C, Castiglione DG, Palumbo GA, Scarso S, Drago F, Gozzo L.   +14 more
europepmc   +1 more source

Clinical Outcomes of Switching From Warfarin to Apixaban or Rivaroxaban in Patients With Atrial Fibrillation: A Nationwide Multidatabase Study. [PDF]

Circ Cardiovasc Qual Outcomes
Kim DH, Ko D, Singer DE, Cervone A, Zhang Y, Chen Q, Lin KJ.   +6 more
europepmc   +1 more source

Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System. [PDF]

J Clin Med
Sridharan K, Sivaramakrishnan G.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Rivaroxaban

Reactions Weekly
  +13 more sources

Rivaroxaban

Drugs of Today, 2007
There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar, Timothy, Watson, Gregory Y H, Lip   +2 more
openaire   +2 more sources